COHR completes Three Cities deal

Article

Independent service organization COHR of Chatsworth, CA, went private this month when it closed a deal to be acquired by investment advisor firm Three Cities Research of New York City. Three Cities paid $6.50 in cash for each of COHR’s outstanding

Independent service organization COHR of Chatsworth, CA, went private this month when it closed a deal to be acquired by investment advisor firm Three Cities Research of New York City. Three Cities paid $6.50 in cash for each of COHR’s outstanding shares.

TCR initiated the deal in December when it bought a 48% interest in COHR from Franklin Research of San Mateo, CA, and Strong Capital Management of Milwaukee (SCAN 1/13/99). The deal gives COHR relief from conducting its business under public scrutiny, but otherwise COHR’s operations should not change as a result of the merger, according to company executives.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.